Update of the pathophysiology of the restless-legs-syndrome.
The Restless Legs Syndrome (RLS) is a heterogeneous disease. Symptomatic or secondary forms encompass iron deficiency, uremia, pregnancy, polyneuropathy, and other causes. The so-called idiopathic RLS syndrome preferentially affects patients with a younger onset before the age of 30. Here we summarize pathophysiological results along the anatomical route, beginning at the cortex and followed by the basal ganglia, thalamus, A11 neurones, substantia nigra, brainstem nuclei, and spinal cord. Genetic risk variants for RLS have recently been identified in two genes, one of them the homeobox gene MEIS1, known to be involved in embryonic development and variants in a second locus containing the genes encoding mitogen-activated protein kinase MAP2K5, and the transcription factor LBXCOR1. A third one, the BTBD9 gene with unknown function encodes a BTB(POZ) domain. Accordingly, new concepts on pathophysiology have to bridge conventional knowledge with possible consequences deriving from these findings. Furthermore, this may create a framework to help understand why dopamine, opioid, and some anticonvulsant therapies are effective in RLS patients.
Paulus
Walter
W
Department of Clinical Neurophysiology, University of Göttingen, Göttingen, Germany. wpaulus@med.uni-goettingen.de
Dowling
Pascal
P
Rijsman
Roselyne
R
Stiasny-Kolster
Karin
K
Trenkwalder
Claudia
C
D006801:Humans; D009420:Nervous System / Q000473:pathology*; D012148:Restless Legs Syndrome / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*